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Heart Failure With Preserved Systolic Function
A Different Natural History?
Michele Senni, MD, FESC,* Margaret M. Redfield, MD, FACC†
Bergamo, Italy, and Rochester, Minnesota
Three well-controlled epidemiology studies in the U.S. have reported that 40% of incident
congestive heart failure (CHF) cases and 50% to 60% of prevalent CHF cases occur in the
setting of preserved systolic function. This condition has been termed “diastolic heart failure”
(DHF). Despite minor differences in the types of populations examined, these community-
based studies have established DHF as a major health problem in the U.S., particularly among
the elderly. Although extensive data are available concerning the natural history of CHF
associated with reduced systolic dysfunction (systolic heart failure; SHF), the natural history
of DHF is not well-characterized. Indeed, it remains unclear whether patients with DHF
share the grim prognosis described for patients with SHF. In this review we examine the
available studies comparing survival observed in patients with DHF to that observed in
patients with SHF. Although there are insufficient data at present to make definitive
conclusions, careful examination of the available studies raises the possibility that the natural
history of patients with DHF may not be different from that observed in patients with CHF
and reduced systolic function. (J Am Coll Cardiol 2001;38:1277–82) © 2001 by the
American College of Cardiology
The Framingham study documented that a clinical diagno-
sis of congestive heart failure (CHF) is associated with a
marked reduction in survival (1,2). The diagnostic criteria
for CHF utilized in the Framingham Study were based on
the history, physical examination, chest radiograph and
response to diuretic therapy and did not include documen-
tation of reduced systolic function. Since this landmark
study, noninvasive techniques to measure systolic function
have become widely available, and reduced systolic function
has rapidly become incorporated into the “diagnostic crite-
ria” for CHF, at least in the context of clinical trials and
most observational studies. However, at the same time a
number of reports describing patients with clinical CHF
and preserved systolic function emerged. These uncon-
trolled, largely hospital-based studies varied widely in their
estimates of the prevalence of preserved systolic function
among patients with CHF and in their descriptions of the
clinical profile of this group of patients (3). More recently,
three well-controlled population-based studies in the U.S.
have reported that 40% of incident CHF cases and 50% to
60% of prevalent CHF cases occur in the setting of
preserved systolic function (4–6). This condition has been
termed “diastolic heart failure” (DHF). Despite minor
differences in the types of populations studied, these epide-
miology studies have established DHF as a major health
problem in the U.S., particularly among the elderly.
HEART FAILURE WITH NORMAL SYSTOLIC FUNCTION
In the face of these reports have come efforts to standardize
the diagnostic criteria for DHF (7,8)—an important step in
the more systematic study of this syndrome. Clearly, there is
a need for more observational data characterizing these
patients, as questions remain about the clinical profile and
natural history of the disorder. Though extensive data are
available concerning the natural history of CHF associated
with reduced systolic function (systolic heart failure; SHF),
the natural history of DHF is not well characterized.
Indeed, it remains unclear whether patients with DHF have
a natural history that is different from the grim prognosis
described in population-based studies for those with CHF
(1,2). In this review we examine the available studies that
compared survival in patients with DHF to that observed in
SHF. Although there are insufficient data at present to
make definitive conclusions, careful examination of the
available studies raises the possibility that the natural history
of patients with DHF may not be different from that of
patients with CHF and reduced systolic function.
THE PROGNOSIS OF PATIENTS WITH DHF IS BETTER
THAN THAT OF PATIENTS WITH SHF
It has become widely accepted that patients with DHF have
a better prognosis than CHF associated with systolic dys-
function (9). This consideration is derived in part from the
established observation that mortality is inversely related to
the left ventricular (LV) ejection fraction among large
numbers of patients with CHF and variable degrees of
reduced systolic function (10). The initial studies describing
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the prognosis of patients with DHF reported annual mor-
tality ranging between 1.3% and 17.5% (3). Moreover, early
studies published in the 1980s and early 1990s comparing
outcomes in CHF patients with preserved versus reduced
systolic function (Table 1) reported that patients with DHF
had a better prognosis than patients with reduced systolic
function. Kinney and Wright (11) reported on 91 patients
(mean age 64 years) referred to an echocardiography labo-
ratory with a diagnosis of CHF. In that study, patients with
decreased fractional shortening had a significantly shorter
median survival (11 months) compared to those with
normal shortening fraction (26 months) (11). Cohn and
Johnson (12) reported that in the Veterans Administration
Cooperative Study (V-HeFT) of middle-aged males (mean
age 60 years) with chronic CHF or impaired exercise
tolerance, annual mortality was 8% in patients with normal
LV ejection fraction compared to 19% in patients with
reduced ejection fraction. In the V-HeFT trial, patients
were considered to have CHF if the diagnosis had been
made in the past or if they exhibited “reduced exercise
tolerance and evidence of cardiac enlargement or left ven-
tricular dysfunction.” Ghali et al. (13) studied 78 patients
(mean age 60 years) admitted to an inner-city hospital with
a diagnosis of CHF. The diagnosis of CHF was based on
the presence of two or more major criteria or the presence of
one major criteria and two minor criteria similar but not
identical to the Framingham criteria (13). Patients with
CHF and preserved LV systolic function were more fre-
quently women, and unadjusted survival was better when
compared to those with impaired function.
In a prospective study of long-term health care facility
residents, Aronow et al. (14) reported that LV ejection
fraction was the most important prognostic factor for
mortality among patients with CHF and coronary artery
disease. Heart failure was diagnosed if pulmonary rales were
heard and pulmonary vascular congestion was present on
chest roentgenogram. Although the mean age of both
groups was 80 years, patients with preserved ejection
fraction were slightly older than patients with reduced
ejection fraction. Unadjusted mortality for patients with
CHF and preserved ejection fraction was lower than that of
patients with reduced systolic function. Mortality rates for
the 81 patients with CHF in their series (14) who did not
have coronary disease were not reported. Thus, these early
studies suggest that patients with CHF and preserved
systolic function have a more favorable prognosis than
patients with CHF and reduced ejection fraction.
THE PROGNOSIS FOR PATIENTS WITH DHF IS
SIMILAR TO THAT OF PATIENTS WITH SHF
In contrast, there are more recent studies (Table 1) that do
not find differences in mortality in patients with CHF and
reduced versus preserved systolic function. In a study of 94
patients (mean age 82 years) treated in a geriatric care unit,
Taffet et al. (15) noted that there was no difference in
survival between patients with CHF and preserved versus
reduced systolic function. In their study, which included
patients with incident and recurrent CHF episodes, the
diagnosis of CHF was confirmed by using a modification of
Framingham criteria. Similarly, in a study of consecutive
CHF admissions to an academic medical center hospital,
McDermott and co-workers (16) found that the cumulative
probability of unadjusted survival at 27 months of follow-up
was equal in patients with CHF and preserved versus
reduced systolic function. All 192 patients (mean age 73
years) included in the McDermott et al. (16) study met the
Framingham criteria for diagnosis of CHF, and patients
with preserved systolic function were more frequently
women. Among 41 patients age 75 to 86 years in the
population-based Helsinki Aging Study, Kupari and col-
leagues (17) found no difference in survival between patients
with CHF and intact versus depressed systolic function.
Heart failure was diagnosed based on a number of clinical
criteria. McAlister et al. (18) studied 566 patients evaluated
in an outpatient CHF clinic; the diagnosis of CHF was
made according to the Framingham criteria. The one- and
three-year survival rates (systolic dysfunction vs. preserved
systolic function) were similar. Patients with preserved
systolic function were older, with a mean age of 69 years.
Pernenkil et al. (19) reported on 501 patients (mean age 81
years) who were admitted to a university hospital with a
diagnosis of CHF. The group with preserved ejection
fraction had a more favorable three months’ unadjusted
mortality than patients with systolic dysfunction (13.5% vs.
23.2%), but unadjusted mortality from 3 to 12 months was
similar in both groups (16.9% vs. 19.4%) (19). Patients with
normal systolic function were older and more frequently
women, compared to those with reduced systolic function.
The diagnosis of heart failure in the Pernenkil et al. study
was based on the presence of either definite radiographic
evidence of pulmonary congestion or typical symptoms and
signs of heart failure associated with a definite clinical
improvement in response to diuretics.
In our study (Senni et al. [5]) of all patients with incident
CHF (Framingham criteria) in Olmsted County, Minne-
sota, in 1991 (n  216; mean age 77 years), 137 had
assessment of ejection fraction within three weeks of diag-
nosis. Of these, 43% had an ejection fraction 50%. In our
study, unadjusted survival was similar between patients with
preserved and those with reduced systolic function (p 
Abbreviations and Acronyms
CAD  coronary artery disease
CHF  congestive heart failure
DHF  diastolic heart failure
LV  left ventricular, left ventricle
SHF  systolic heart failure
VA  Veterans Administration
V-HeFT  Veterans Administration Cooperative Study
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Table 1. Studies Comparing Survival Among Patients With CHF and Preserved (DHF) or Reduced (SHF) Systolic Function
Study–Year
of Publication
No. of
Patients
(% DHF)
Mean Age
(yrs) CHF Diagnosis Mortality–SHF Mortality–DHF
p Value
SHF vs. DHF
Mortality
Studies where mean age 65 yrs
Warnowicz–1983 (22) 39 (41%) DHF 63  9 Acute pulmonary edema 30% (9 mo) 25% (9 mo) NS
SHF 66  11
Kinney–1989 (11) 91 (48%) All 64  10 2 major or 1 major  1 minor§ Median survival  11 mo Median survival  26 mo 0.01
Cohn–1990 (12) 623 (13%) DHF 60  7 VO2max 25/ml/kg/min 19% (annualized) 8% (annualized) 0.0001
SHF 58  8
Ghali–1992 (13) 78 (28%) DHF 60  11 2 major or 1 major  2 minor§ 24% (1 yr) 22% (1 yr) 0.04
SHF 59  14 46% (2 yr) 26% (2 yr)
Studies where mean age 65 yrs
Aronow–1990 (14) 166 (40%) DHF 84  6 Rales  CXR vascular congestion 47% (1 yr) 22% (1 yr) 0.001
SHF 81  8 71% (2 yr) 38% (2 yr)
Taffet–1992 (15) 94 (43%) DHF 82  na Framingham 24% (1 yr) 24% (1 yr) NS
SHF 83  na 42% (2 yr) 30% (2 yr) NS
McDermott–1997 (16) 192 (46%) DHF 73  na Framingham 35% (27 mo) 35% (27 mo) NS (0.78)
SHF 72  na
Kupari–1997 (17) 41 (51%) ALL  80 Other† 54% (4 yr) 43% (4 yr) NS
Permenkil–1997 (19) 501 (34%) DHF 81  6 Other‡ 38% (1 yr) 28% (1 yr) p  0.045
SHF 78  6 19% (3–12 mo) 17% (3–12 mo) p  NS
Senni–1998 (5) 137 (43%) DHF 78  12 Framingham 24% (1 yr) 24% (1 yr) NS (0.369)
SHF 74  13 42% (3 yr) 42% (3 yr)
McAlister–1999 (18) 566 (21%) DHF 69  14 Framingham 17% (1 yr) 12% (1 yr) NS (0.25)
SHF 65  14 38% (3 yr) 42% (3 yr)
Vasan–1999 (4) 73 (51%) DHF 72  9 Framingham 64% (5 yr) 32% (5 yr) p  0.023
SHF 74  7 Adj*p  0.13
Ansari–2001(abstr) (23) 376 (27%) ALL 72  na Framingham 20% (20 mo) 20% (20 mo) NS
*In a multivariate model correcting for age and gender, the hazard ratio (95% confidence intervals) for death for “CHF with normal ejection fraction” was 0.59 (0.30–1.16), p  0.13. The group with DHF was predominantly women.
†Three of four criteria present: 1) shortness of breath on ordinary effort; 2) S3 or heart rate 90 beats/min; 3) pulmonary venous congestion on chest radiograph or jugular venous distension or hepatomegally; and 4) cardiothoracic ratio
0.55 on chest radiograph. ‡Definite radiographic evidence of CHF or typical symptoms and signs of CHF in conjunction with definite clinical improvements in response to diuretic. §Major and minor criteria are similar to those specified
in the Framingham criteria.
Adj  adjusted; CHF  congestive heart failure; CXR  chest radiograph; DHF  diastolic heart failure; na  not available; NS  not significant (p value when available); SHF  systolic heart failure.
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0.279) (5). Survival adjusted for age, gender, New York
Heart Association functional class, and coronary artery
disease (CAD) was still not significantly different in the two
groups (relative risk  0.80; p  0.369).
We recently repeated a review of all patients with
new-onset CHF and preserved systolic function in Olmsted
County, Minnesota, during 1996 and 1997 (n  83; mean
age 77 years) (20,21). In a preliminary report, Chen et al.
(21) indicate that the survival curves in this population-
based study of patients with incident CHF and preserved
systolic function are identical to those observed in the 1991
cohort. These data confirm our earlier findings regarding
the poor outcome in patients with incident CHF and
preserved systolic function in the community.
In a small study of 39 patients (mean age 63 years) who
had myocardial infarction and acute pulmonary edema,
Warnowicz and colleagues (22) found a similar nine-month
mortality rate in patients with normal or reduced systolic
function. In 73 patients (mean age 73 years) with a history
of CHF who underwent echocardiography as a part of the
Framingham study, Vasan et al. (4) found that mortality
adjusted for age and gender was not significantly lower in
patients with normal systolic function. In that study of
prevalent CHF, unadjusted mortality was lower in patients
with preserved systolic function. The mean time from CHF
diagnosis to echocardiography was 2.8 years (range 0.1 to 15
years). Patients with normal systolic function were older and
more frequently women, compared to those with systolic
dysfunction. Recent preliminary data from Ansari et al. (23)
in a large Veterans Administration (VA) cohort of elderly
(mean age 72 years), primarily male patients with a diag-
nosis of CHF confirmed by Framingham criteria show
identical survival curves (mean follow-up 20 months) for
those with preserved and those with reduced systolic func-
tion.
WHY DO STUDIES DIFFER?
The factors responsible for the disparate findings regarding
outcomes in CHF patients with preserved or reduced
systolic function reported in these studies remain unclear.
We note that most studies reporting a better prognosis for
those with CHF and preserved systolic function were
performed in younger cohorts of CHF patients (mean age
65 years). The Aronow et al. (14) study (mean age 84
years) is an exception and reported only on those patients
with CHF and CAD, excluding 81 patients with CHF who
did not have coronary disease. Those studies that did not
show a survival difference between CHF and preserved
versus reduced systolic function examined older populations
(mean age 65 years; Table 1). It may be that the natural
history of DHF in younger individuals is different from that
observed in the elderly. As previously reported, the preva-
lence of DHF increases significantly with age. Indeed, heart
failure secondary to diastolic dysfunction is primarily a
disorder of advanced age. Thus, findings in elderly cohorts
may be more germane to the majority of patients with CHF
and preserved systolic function.
Another factor that might play a role in the different
prognoses reported in available studies is the choice of
diagnostic criteria for CHF. In the early studies reporting
relatively better outcomes in those with DHF, the criteria
were more liberal and less specific compared to the Fra-
mingham criteria used in the later studies, which did not
find survival differences (Table 1). Thus, it is possible that
the group with preserved systolic function may have in-
cluded patients with noncardiac symptoms, as has recently
been reported by Caruana et al. (24) in patients with
“suspected heart failure.” Although the Framingham criteria
are relatively insensitive for the detection of early manifes-
tations of CHF, they have a high sensitivity and specificity
for the detection of definite CHF (25). These findings
underscore the need for standardized clinical criteria for
CHF diagnosis. Difficulty establishing the clinical diagnosis
often occurs when assessing elderly patients with co-
morbidities and when the diagnosis of CHF is made by a
noncardiologist, factors often present in patients with CHF
and preserved systolic function.
Various other factors influence the natural history of
CHF that were not controlled for in the observational
studies reviewed here. Primary among these factors is the
type of population studied, which varies widely in the
reports analyzed in this review and includes hospitalized
patients, patients referred to an imaging laboratory, resi-
dents of long-term care facilities, patients seen in a geriatric
care center, patients participating in a multicenter study,
patients seen in an outpatient CHF clinic, patients seen in
the VA system and population-based studies. Studies also
can vary as to whether the patients enrolled are presenting
with a first-time or subsequent episode of CHF; this is often
not specified. Studies vary as to whether ejection fraction
was measured during the CHF episode or at a significantly
later date. Findings from a recent study would suggest that
if ejection fraction was found to be normal some days after
presentation with acute pulmonary edema, it was usually
normal during the pulmonary edema episode (26). In
contrast, a significant number of patients who had normal
ejection fraction months to years after a CHF episode had
reduced ejection fraction during the CHF episode (27).
Indeed, more patients with CHF and reduced systolic
function may normalize their ejection fraction with standard
therapy in the beta-blocker era. Thus, studies of incident
CHF may have findings different from those that include
patients with both incident and recurrent CHF.
As most studies characterizing the prognosis of patients
with CHF and reduced versus preserved systolic function
were observational, therapeutic management was not stan-
dardized, and this could influence survival in these retro-
spective studies. Indeed, recent retrospective cohort studies
suggest that treatment with angiotensin-converting enzyme
inhibition and beta-blockers may improve survival in pa-
tients with DHF (21,28). Although these studies do not
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offer definitive proof that such agents are of benefit in
patients with DHF, they do suggest that differences in
treatment not controlled for in observational studies may
influence findings regarding outcomes in different patient
groups.
In addition, racial and socioeconomic differences may also
exist in different studies and influence findings. A prelimi-
nary study from an inner-city urban hospital with a large
percentage of African American patients reports that sub-
jects with CHF and preserved systolic function were
younger (mean age 60 years) than in most series, but
outcomes in this population were not assessed (29).
CLINICAL IMPLICATIONS
This growing body of literature challenges the conventional
belief regarding the natural history of DHF, particularly
when there is a well-confirmed clinical diagnosis of CHF
and when elderly cohorts are studied. Indeed, eight of the
nine series in elderly cohorts with CHF report similar or
marginally different mortality rates among those with pre-
served and reduced systolic function. Viewed in aggregate,
these studies strongly suggest that, among the elderly, the
clinical syndrome of CHF (when definitively characterized)
carries a uniformly poor prognosis regardless of the level of
systolic function. There are several important clinical im-
plications of these data.
First, they should serve to heighten appreciation of the
importance of the syndrome of DHF in the elderly and
impress upon the physician the need for aggressive manage-
ment both for improvement in survival and reduction of
readmission and other morbidity associated with CHF.
Rates of readmission usually parallel mortality statistics.
Whereas some studies have suggested that readmission rates
for DHF are lower than for those observed with CHF and
reduced systolic function (5,16), preliminary findings from
an inner-city hospitalized CHF population reports similar
re-hospitalization rates for those with CHF and preserved
or reduced systolic function (30). Although there is no
proven treatment for DHF per se, most patients with DHF
have hypertension and/or CAD, and aggressive therapy of
these underlying conditions is available and proven to
reduce CHF (31).
A second important implication of these studies relates to
efforts to engender support for treatment trials in DHF. In
order for these efforts to proceed, data regarding event rates
and their relation to the type of population studied are
crucial when designing the study size. These data would
suggest that if the population enrolled is elderly, with
well-defined and advanced CHF, event rates (and sample
size) would be similar to those used in trials for CHF with
reduced systolic function. However, should only younger
patients or patients with milder CHF not satisfying Fra-
mingham criteria be enrolled, the event rates would be
lower, and larger sample sizes would be required. Because
trials in CHF and systolic dysfunction have traditionally
enrolled younger and more predominantly male popula-
tions, different enrollment strategies may be needed to study
DHF. Data such as those summarized here, as well as
enhanced efforts to standardize diagnoses (7,8), are needed
if efforts to provide an evidence-based approach to this
growing and important clinical syndrome are to succeed.
Conclusions. Although the natural history of DHF will
probably continue to be debated, review of the available data
confirms the seminal observations from the Framingham
study, where the poor prognostic implications of the clinical
diagnosis of CHF were established prior to widespread
assessment of ejection fraction. We conclude that, at least
among the elderly, the clinical diagnosis of CHF portends a
grim prognosis that is independent of the level of measured
ejection fraction.
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